CN109157540A - Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament - Google Patents
Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament Download PDFInfo
- Publication number
- CN109157540A CN109157540A CN201811391195.1A CN201811391195A CN109157540A CN 109157540 A CN109157540 A CN 109157540A CN 201811391195 A CN201811391195 A CN 201811391195A CN 109157540 A CN109157540 A CN 109157540A
- Authority
- CN
- China
- Prior art keywords
- medical stone
- disease
- treatment
- application according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
The present invention relates to new effect of medical stone single medicinal material, the present invention is had found by lot of experiments, and medical stone can be improved the diversity of enteric microorganism and promote a variety of growth of probiotics, improves immunity of organisms；And medical stone has effects that prevent and/or treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance related disease, adverse reaction bottom are highly-safe.
Description
Technical field
The present invention relates to the new applications of medical stone, and in particular to medical stone prevents and treats anaphylactia, mental disease in preparation
Application in disease, metabolism class disease and endocrine disturbance disease medicament.
Background technique
Each age level of the anaphylactia from newborn to the elderly may all occur.Anaphylactia main Types
There are cutaneous anaphylaxis, respiratory tract anaphylaxis reaction, alimentary canal allergic reaction and anaphylactic shock etc., common disease has following several
Kind: allergic dermatitis, allergic rhinitis, allergic asthma, anaphylactoid purpura, anaphylactic shock, irritable bowel disorder, anaphylaxis first
Shape adenositis, allergic nephritis, interstitial cystitis etc..Wherein allergic dermatitis includes drug rash, contact dermatitis, eczema, nettle
Rash, dermographism, food hypersenstivity and environmental factor cause allergy.Irritable bowel disorder is primarily referred to as allergic colitis, ulcer
Property colitis and Crohn disease.
In recent years, the disease incidence of anaphylactia increases year by year, brings heavy financial burden to society and causes huge
Huge economic loss has become serious public health problem.
The treatment of anaphylactia mainly uses Loratadine and hormone medicine, and Loratadine such as flutters you
Quick, Astemizole, quick gram, Clarityne etc..Antihistamine drug has side effect, and long-time service can make one drowsiness, tired, mental slow
It is blunt.Hormone medicine such as mainly has cortex hormone of aadrenaline, such as prednisone, dexamethasone and cyclophosphamide, imuran
Deng, conventional Hormone can the internals such as serious liver injury, kidney, also will affect the growth and development of children.
In addition, as people's lifestyle changes, a variety of mental disorders, metabolism class disease and endocrine disorder
Increase year by year, there is great influence to the health of the mankind.
Summary of the invention
Goal of the invention: the purpose of the present invention is screening by many experiments, furtheing investigate medical stone, it is new to develop it
Clinical efficacy.
In order to solve the above technical problems, the technical solution adopted by the present invention is that:
Medical stone is in preparation prevention and/or treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance
Application in related disease drug.
The anaphylactia includes allergic dermatitis, allergic rhinitis, allergic asthma, anaphylactoid purpura, allergy
Property shock, anaphylaxis thyroiditis, allergic nephritis, interstitial cystitis, irritable bowel disorder etc..
The allergic dermatitis include drug rash, contact dermatitis, eczema, nettle rash, dermographism, food hypersenstivity with
Environmental factor causes allergy dermatitis；Irritable bowel disorder includes allergic colitis, ulcerative colitis and Crohn disease.
The mental disorder includes depression, autism or senile dementia disease.
The metabolism class disease includes high blood pressure, diabetes or obesity.
The endocrine disturbance related disease include whelk, female irregular menstruation disease, sleep disturbance, be hard and dry and
Constipation.
Medical stone improves immunity of organisms, improves the diversity of enteric microorganism and promotes a variety of growth of probiotics in preparation
Drug in application.
Medical stone and pharmaceutically acceptable carrier can be prepared into oral preparation or external preparation by the present invention.The medicine
The solid or liquid form that object can take orally can also be made external application and smear ointment preparation or powder.
Medical stone provided by the invention can increase the type and quantity of probiotics, the especially kind of increase actinomyces door bacterium
Class and quantity.
Medical stone provided by the invention can reduce influence of the antibiotic for intestinal microecology, promote intestinal microecology used
It restores balance as early as possible after antibiotic.
As an improvement of the present invention, medical stone provided by the invention can individually be taken, can also be with any food
With integration of drinking and medicinal herbs food, and mixes and take without antergic Chinese medicine or Western medicine.
The present invention compared with the prior art, has the advantage that as follows:
1) medical stone provided by the invention is a kind of natural silicate mineral, scientific name quartz monzonite.Medical stone contains
Oxide and a variety of inorganic ions, have and adjust micro-ecological in intestines and anabolic action；Contained oxide and inorganic
A variety of probiotics play trophism in the micro- state of ion pair enteron aisle.
2) for medical stone provided by the invention by adjusting intestinal microecology, having further stimulates panimmunity cell development
Effect；Required nutrients of many oxide and ion that medical stone contains as a variety of probiotics, supports the growth of probiotics,
Probiotics can further stimulate the development of immunocyte, further maintain immunologic balance, reach prevention and treatment anaphylaxis disease
The effect of disease.
3) a variety of probiotics of nutrition of the present invention generate immune factor by the development of stimulation immunocyte, these are immune
The factor further adjusts the development of children's brain and nerve, therefore has the function of adjusting neurodevelopment.
4) a variety of probiotics metabolites of nutrition of the present invention, adjustable human endocrine activity, reach prevention and control
Treat a variety of diseases caused by endocrine disturbance.
Specific embodiment
The preferred embodiments of the present invention will be described in detail below so that advantages and features of the invention can be easier to by
It will be appreciated by those skilled in the art that so as to make a clearer definition of the protection scope of the present invention.
Embodiment 1
Treat autism
(1) prepared by preparation: medical stone crushes, and high pressure sterilization is spare.Auxiliary material is high-quality dry corn flour and wheat bran, medical stone
Powder: corn flour: soy meal is 1:2:1 (mass ratio), capsule is made, 0.5 gram of drug containing in each capsule makes rear spare.
(2) autism research object: Autism children 60 are recruited as research subject, patient passes through Americanism obstacle
The diagnostic criteria of diagnostic and statistical manual (DSM- IV) childhood autism is made a definite diagnosis, the age less than 3.0 years old, wherein boy 40,
Girl 20.In these subjects, slight self-closing disease infant 18, moderate self-closing disease infant 22, severe self-closing disease infant 20
Example.Experimental subjects is randomly divided into two groups, treatment group and control group, every group of 30 people, patients with mild 9, moderate patient 11, severe
Patient 10.
(3) treatment method: treatment group takes orally medical stone capsule and 3 tablets each time, is mixed and takes with food 2 times a day.
Therapeutic effect evaluation and test is carried out after medication 3 months.Control group takes placebo made of the auxiliary material of same ratio.During medication, suffer from
Person normally participates in rehabilitation and normal diet.Change pretherapy and post-treatment using high-flux sequence instrument detection enteric microorganism simultaneously
Change.
(4) treatment effectiveness evaluation: CARS scale, ABC scale, Gesell developmental scale (social adaptation are used before and after treatment
DQ, personal social activity DQ, language DQ), it is evaluated and tested using items of the questionnaire form to autism children.The data of acquisition use
18.0 software of SPSS is for statistical analysis.
(5) result: the pretherapy and post-treatment CARS scale for the treatment of group, ABC scale numerical value significant difference (P ﹤ 0.05) as the result is shown, and
Control group scores no significant change before and after treatment.Compared with the control group, CARS, ABC scale score are obvious for treatment group after treatment
It reduces, significant difference (P ﹤ 0.05) the results are shown in Table 1.Treatment group's infant social adaptation DQ, language DQ, personal social activity DQ after treatment
Value is significantly raised compared with the control group, significant difference (P ﹤ 0.05).It the results are shown in Table 1 and table 2.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 3), actinomyces door
Bacterial species and quantity dramatically increase (P ﹤ 0.01).
Table 1CARS scale, ABC scale score compare
The scoring of table 2Gesell developmental scale
The type that 3. random forest of table analysis treatment group enteric bacteria content dramatically increases
2 medical stone of embodiment treats the experimental study that allergic asthma merges Allergic Rhinitis
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry pearling cone meal and wheat flour, wheat meal
Mountain flour, pearling cone meal and wheat flour mixed proportion are medical stone powder: pearling cone meal: corn flour is 3:1:2 (mass ratio), and capsule is made,
0.5-0.55 grams of drug containing in each capsule makes rear spare.
(2) allergic asthma merges allergic rhinitis subject selection: 88 sensitive asthmatics merge Allergic Rhinitis with
Machine is divided into treatment group and control group.Treatment group 44, male 26 are female 18, the age 7~60 years old, 32.0 ± 13.4 years old average.Disease
Journey 1~20 year, average (5 ± 7.8) year；Control group 44, male 25, female 19, the age 6~59 years old, average (33.5 ±
12.1) year；The course of disease 1~20 year, average (6 ± 6.3) year.Two groups of subject Genders, age, course of disease no difference of science of statistics.Enter
Case is selected to meet allergic asthma and allergia nose's inflammation diagnostic criteria (allergic asthma diagnostic criteria: with reference to Chinese Medical Association
" prevention and control of bronchial asthma guide (2008) " that respirology branch asthma group is formulated).
(3) treatment method: medical stone capsule is taken by treatment group, 2 times a day, 5 tablets/time of dosage, can be mixed with food
It takes.Therapeutic effect evaluation and test is carried out after medication 3 months.Control group takes placebo made of the auxiliary material of same ratio.It adopts simultaneously
The detection of enteric microorganism variation is carried out with high-flux sequence instrument.
(4) treatment effectiveness evaluation: after treatment 3 months, therapeutic effect is observed.
1. Asthma control standards of grading: it is 25 points that asthma, which fully controls scoring, and it is 20~24 points that Asthma control, which well scores,
It is that < 20 divides that asthma, which does not control scoring,.
2. Rhinitis Symptoms standards of grading: A. is commented referring to the allergic rhinitis in " allergic rhinitis processing is pocket to refer to 2009 "
The symptom of minute mark quasi- evaluation patient.Pretherapy and post-treatment Rhinitis Symptoms scoring is completed by the same veteran doctor.
B.RQLQ marking scales: it scores before and after treatment.
3. serum total Ig E detects: limosis vein blood, kit detect IgE content.
4. allergic rhinitis index of assessment of curative effect: improvement rate is by [(total score after total score-treatment before treating)/treatment is preceding total
Point] * 100% calculating, wherein Xian Xiao≤51%；,≤21% of You Xiao≤50%；Wu Xiao≤20%.
5. total effective rate: effectively: asthma scoring is 25 points, meanwhile, allergic rhinitis therapeutic evaluation Zhi Biao≤51%；It is good
Turn: asthma scoring is 20~24 points, while allergic rhinitis therapeutic evaluation Zhi ,≤21% of Biao≤50%；It is invalid: asthma < 20
Point, while allergic rhinitis therapeutic evaluation Zhi Biao≤20%.
(5) result: the data of acquisition are for statistical analysis using 18.0 software of SPSS.The results show that medical stone capsule system
The effective percentage of agent treatment is significantly higher than control (15.9%), the results are shown in Table 4 and table 5 up to 93.2%.
(6) variation of enteric microorganism: high-flux sequence instrument sequencing analysis 16s rRNA is used, as the result is shown treatment group's intestines
The diversity of road microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 6), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
4. pretherapy and post-treatment two groups of patient view's Indexes Comparisons of table
5. two groups of patients of table treat total effect and compare (example)
| Group | Number of cases | Effectively | It improves | In vain | Total effective rate |
| Treatment group | 44 | 32 | 9 | 3 | 93.2% |
| Control group | 44 | 3 | 4 | 37 | 15.9% |
| P value | <0.001 |
Note: through Chi-square Test: df=1, X2=52.983, P < 0.001.
The type that 6. random forest of table analysis treatment group enteric bacteria content dramatically increases
The experimental study of 3 medical stone of embodiment treatment eczema
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry corn flour and soybean powder, wheat meal
Stone traditional Chinese medicine powder, corn flour and soybean powder mixed proportion are medical stone powder: wheat bran: soybean powder is 2:5:1 (mass ratio), and tabletting is made
Tablet, each tablet weight are 0.5 gram, are made rear spare.
(2) adult eczema subject selection: 90 patients are randomly divided into treatment group and control group.Treatment group 45, male 24,
Female 21, the age 13~63 years old, average (33.6 ± 6.4) year.The course of disease 1~20 year, average (9.7 ± 8.1) year；Control group 45
Example, male 23, female 22, the age 13~65 years old, average (32.4 ± 8.6) year；The course of disease 1~19 year, average (10.1 ± 7.7)
Year.Two groups of subject Genders, age, course of disease no difference of science of statistics.Selected case meets eczema diagnostic criteria.
(3) treatment method: treatment group's above-mentioned medical stone tablet orally three times a day, 3 times a day, 5 tablets once.Control group is adopted
It is handled with the auxiliary material of same ratio.Therapeutic effect evaluation and test is carried out after medication 6 months.
(4) treatment effectiveness evaluation: after treatment 6 months, 9 months after drug withdrawal, therapeutic effect is observed.Criterion of therapeutical effect is cured: skin
Rash all subsides, and pruritis disappears；Effective: 80% or more deflorescence, pruritis is substantially reduced；Improve: skin subsides
50%, pruritis does not mitigate；Invalid: deflorescence is unobvious, and pruritis does not mitigate or in vain.With healing, effective case
Number is total to calculate effective percentage.
(5) result: treated effect as the result is shown is shown in Table 7.According to statistical analysis, treatment group and the clinical of control group are treated
There were significant differences (P < 0.001) for effect.It has no adverse reaction.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 8), actinomyces door
Bacterial species and quantity dramatically increase (P ﹤ 0.01).
7 two groups of patients of table treat total effect and compare (example)
| Group | N | It cures | It is effective | It improves | In vain | Effective number of cases | It is efficient |
| Treatment group | 45 | 32 | 9 | 2 | 2 | 41 | 91.1% |
| Control group | 45 | 2 | 6 | 6 | 31 | 8 | 17.8% |
| P value | P < 0.001 |
Note: through Chi-square Test: df=1, X2=48.785, P < 0.001.
The type that 8 random forest of table analysis treatment group enteric bacteria content dramatically increases
4 medical stone antihypertensive function experimental study of embodiment
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry pearling cone meal and soybean powder, wheat meal
Mountain flour, corn flour and soybean powder mixed proportion are medical stone powder: pearling cone meal: adlay rice flour is 1:5:1 (mass ratio), and piece is made
Agent, each tabletting weight are 0.5 gram, are made rear spare.
(2) hypertensive patient selects: 80 meet I grades of hypertensive patients, are randomly divided into treatment group and control group.Treatment group
40, male 20, female 20, the age 33~66 years old, average (51 ± 9.7) year.Control group 40, male 20, female 20, the age
35~66 years old, average (50.8 ± 10.2) year.Two groups of subject Genders, age, course of disease no difference of science of statistics.It is tested non-medication
Object or after deactivated depressor 1 week signs informed consent form.
Selected case meet TCM syndrome diagnostic criteria (drug surveilance office of the People's Republic of China (PRC) (2002) it is specified " in
Medicine Clinical Researches of New Drugs guideline " type of deficiency of YIN leading to hyper activity of YANG primary symptom), and meet the tetra- Hypertension Guideline diagnosis marks of WHO/SH in 1999
It is quasi-: the non-drug state lower 2 times or 2 times or more non-blood pressure determination averaging of income values that repeat on the same day: systolic pressure 140mmHg and/or easypro
Pressure 90mmHg is opened, level-one hypertension 140~159/90~99 requires to need drug therapy according to Hypertension Guideline.
Exclusion criteria: 1. acute coronary syndrome (ACS)；2. in acute apoplexy event 1 month；3. secondary high blood
Pressure, hypertensive crisis；4. secondary patients with dyslipidemia；5. II grades and II grades or more hypertensive patient；6. type-1 diabetes mellitus and II
Patients with type Ⅰ DM merges the acute metablize confusion；7. wound was performed the operation in 3 months；8. in acute infectious diseases 1 month；9. patient has
Obvious reason, is not able to cooperate the person of completion.
(3) treatment method: treatment group takes orally 3 medical stone tablets daily, 4 tablets each time.Control group is using at conventional method
Reason is abandoned with any drug therapy automatically.Therapeutic effect evaluation and test is carried out after medication 12 weeks.
(4) treatment effectiveness evaluation: treatment time is 12 weeks, 4 weeks after drug withdrawal, evaluates therapeutic effect.Sign observation: before treatment
1,4,7d after l d and treatment start, later 2 times/week, set time (morning 8:00-10:00；Afternoon 15:00-17:00) monitoring
Blood pressure is surveyed be averaged twice weekly, and measured's peace and quiet are rested 10 minutes, takes seat right upper extremity blood pressure.
Symptom Observation: observation dizziness, headache, palpitaition, insomnia, tinnitus.
Criterion of therapeutical effect is effective: diastole drops 10mmHg and dropping to normal or decline 20mmHg or more after treatment, shrinks
Pressure drop is to normally.Effective: diastole drops are not up to 10mmHg after treatment, but oneself drops to normal range (NR), or decline 10-
19mmHg, for example systolic hypertension shrink drops 30mmHg.Invalid: blood pressure decline is not up to effective standard after treatment.
Symptom curative effect determinate standard: 1. effective: clinical symptoms are obviously improved integral Jian Shao≤70%；2. effectively: clinic has
It is improved, symptom integral subtracts few≤30%；3. invalid: clinical symptoms are not improved, even it aggravates, symptom integral Jian Shao≤
30%.
(5) result: treated effect as the result is shown is shown in Table 9.According to statistical analysis, treatment group and the clinical of control group are treated
There were significant differences (P < 0.001) for effect.It has no adverse reaction.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 10), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
Curative effect compares (n, %) after 9 two groups of patients of table treat 1 month
| Group | N | It is effective | Effectively | In vain | Effective number of cases | It is efficient |
| Treatment group | 40 | 23 | 13 | 4 | 36 | 90.0% |
| Control group | 40 | 4 | 3 | 33 | 7 | 17.5% |
Note: through Chi-square Test: df=1, X2=42.288, P < 0.001.
The type that 10 random forest of table analysis treatment group enteric bacteria content dramatically increases
The research of 5 medical stone function of blood sugar reduction of embodiment
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-grade maize powder, soybean powder and wheat
Powder, mixed proportion are medical stone powder: corn flour: soybean powder is 2:5:1 (mass ratio), and tablet is made, and each tabletting weight is 0.5
Gram, it makes rear spare.
(2) type-2 diabetes mellitus subject selection: 88 patients are randomly divided into treatment group and control group.Treatment group 44, male 22
Example, female 22, the age 40~66 years old, average (45.3 ± 4.6) year.The course of disease 1~16 year, average (7.9 ± 5.3) year；Control group
44, male 22 is female 22, the age 40~68 years old, (43.8 ± 5.6 years old average；The course of disease 1~15 year, average (7.3 ± 4.9)
Year.Two groups of subject Genders, age, course of disease no difference of science of statistics.Selected case meets the standard (reference of diabetes diagnosis
Standard of the ADA in 1998 about diabetes diagnosis), it is diagnosed as diabetes B department of traditional Chinese medicine out-patient.
Chinese medical discrimination has in following real example in 3 and asthenic symptoms 2.
Real example: addiction delicious food, gastral cavilty turgor, hiccup is rotten, ozostomia, dirty smelly of defecating, side of body rib turgor pain, and irritability is burnt
Worry, rapid digestion of food and polyorexia, constipation, extreme thirst, irregular menstruation, limbs are heavy, and the swollen limb of greasy or hand is sticked in mouth and is swollen, indigestion and loss of appetite just to stick, irritable
Irritability, vexed bitter taste, dry and hard excrement.Asthenic symptoms: dry, polydipsia, polyorexia, dysphoria in chestpalms-soles, soreness and weakness of waist and knees, dizziness ear
Ring.
(3) treatment method: 88 out-patients keep former therapeutic scheme and diet motion scheme constant.From the day of observation
It rises, treatment group takes orally 2 medical stone tablets daily, 6 tablets each time.Control group is handled using conventional method.It is deactivated after medication 90 days
10 days, then carry out therapeutic effect evaluation and test.
(4) hypoglycemic efficacy evaluation: after treatment 90 days, 10 days observation therapeutic effects after drug withdrawal.Criterion of therapeutical effect is effective: treatment
30% or more decline before fasting blood-glucose < 7.0mmol/L or 2h-plasma glucose < 7.8mmol/L or hypoglycemic amplitude are relatively treated afterwards；Have
Effect: decline before fasting blood-glucose < 8.3mmol/L or 2h-plasma glucose < 11.0mmol/L or hypoglycemic amplitude are relatively treated after treatment
10%~30%；Invalid: blood glucose decline does not reach above-mentioned standard person after treatment.Effective percentage is calculated so that effective, effective case load is total.
(5) result: treated effect as the result is shown is shown in Table 11.According to statistical analysis, treatment group and the clinical of control group are treated
There were significant differences (P < 0.001) for effect.It has no adverse reaction.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 12), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
Curative effect compares (n, %) after 11 two groups of patients of table treat 9 months
| Group | N | It is effective | Effectively | In vain | Effective number of cases | It is efficient |
| Treatment group | 44 | 25 | 14 | 5 | 39 | 88.6% |
| Control group | 44 | 3 | 3 | 38 | 6 | 13.5% |
Note: through Chi-square Test: df=1, X2=49.526, P < 0.001.
The type that 12 random forest of table analysis treatment group enteric bacteria content dramatically increases
6 medical stone of embodiment treats whelk functional study
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry corn flour and soybean powder, wheat meal
Mountain flour, corn flour and soybean powder mixed proportion are medical stone powder: corn flour: mung bean flour is 2:3:1 (mass ratio), and tablet is made,
Each tabletting weight is 0.5 gram, is made rear spare.
(2) whelk patient is tested selection: 50 patients are randomly divided into treatment group and control group.Treatment group 25, male 15
Example, female 10, the age 11~18 years old, average (13.5 ± 2.9) year.The course of disease 1~4 year；Control group 25, male 14, female 11,
Age 11~19 years old, average (14.1 ± 3.9) year；The course of disease 1~4 year.Two groups of subject Genders, age, courses of disease are without statistics
Difference.Selected case is that experienced dermatologist is diagnosed as whelk.
(3) treatment method: treatment group daily take orally medical stone preparation, daily 4.Control group is handled using conventional method.
Therapeutic effect evaluation and test is carried out after medication 4 weeks.
(4) it treatment effectiveness evaluation: is drafted according to " disease of tcm Standardization of diagnosis and curative effect " in conjunction with clinic.It cures: skin lesion
Subside, subjective symptoms, which disappears, to improve；Improve: subjective symptoms is substantially reduced, 30% or more skin lesion recession；It is not cured: skin lesion and symptom
Unchanged or recession is not as good as 30%.To cure, improvement case load it is total calculate it is efficient.
(5) result: treated effect as the result is shown is shown in Table 13.According to statistical analysis, treatment group and the clinical of control group are treated
There were significant differences (P < 0.001) for effect.It has no adverse reaction.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 14), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
Curative effect compares (n, %) after 13 two groups of patients of table treat 4 weeks
| Group | N | It cures | It improves | In vain | Effective number of cases | It is efficient |
| Treatment group | 25 | 13 | 8 | 4 | 21 | 84% |
| Control group | 25 | 2 | 4 | 19 | 6 | 24% |
Note: through Chi-square Test: df=1, X2=18.116, P < 0.001.
The type that 14. random forest of table analysis treatment group enteric bacteria content dramatically increases
7 medical stone adjuvant therapy of depression functional study of embodiment
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry wheat bran, corn flour and soya bean
Powder, medical stone powder, wheat bran, corn flour and soybean powder mixed proportion are medical stone powder: wheat bran: soybean powder is 1:3:1 (mass ratio),
Tablet is made, each tabletting weight is 0.5 gram, is made rear spare.
(2) depression subject selection: 60 patient volunteers meet the diagnostic criteria (" Chinese Spirit of depressive illness
Obstacles classification and diagnostic criteria ", the 3rd edition).Subject is randomly divided into observation group, totally 30, male patient 15, female patient
15, the age 15~62 years old, average (32.4 ± 10.5) year, average course of disease (10.8 ± 4.9) moon；Control group 30, male suffers from
Person 14, female patient 16, the age 15~63 years old, average (33.1 ± 7.9) year, average course of disease (10.7 ± 5.9) moon.Two groups
Patient is in the indexs such as age, gender, the course of disease, no difference of science of statistics.
(3) treatment method: before administration, observation group and control group subject are all provided with the cleaning phase 2 weeks, avoid other depressed drugs pair
The influence of this research.Observation group takes orally 1 medical stone preparation, 6 tablets each time in addition to using effect of paroxetine in treating daily.Control group
Using effect of paroxetine in treating.Therapeutic effect evaluation and test is carried out after 12 week of medication.
(4) treatment effectiveness evaluation: treatment different periods, using Hamilton Depression Scale (Hamilton Depression
Scale, HAMD) scoring and comparative analysis, before treatment, substantially quite, group difference is without statistics for the HAMD scoring of two groups of patients
Learn meaning.And being obviously improved occur in 4 weeks, 6 weeks, 10 weeks, 12 weeks after treating, HAMD scoring of the observation group compared with control group patient,
Group difference has statistical significance (P < 0.05), is shown in Table 15.
The HAMD index scoring situation of 15 two groups of patients of table
| Group | It is tested quantity | Before treatment | Treatment 4 weeks | Treatment 6 weeks | Treatment 10 weeks | Treatment 12 weeks |
| Observation group | 30 | 26.39±4.37 | 14.36±3.69 | 11.69±4.63 | 10.42±3.63 | 8.01±3.31 |
| Control group | 30 | 27.01±3.96 | 22.34±4.81 | 17.14±3.54 | 14.27±4.50 | 12.74±4.27 |
| t | -0.576 | -7.210 | -5.122 | -3.647 | -4.795 | |
| P | 0.570 | <0.001 | <0.001 | <0.001 | <0.001 |
A situation arises compares for the adverse reaction of (5) two groups of patients: during treatment, two groups of patients occur dry, perspiration,
The adverse reactions such as Nausea and vomiting, weight gain, food is fuzzy, still, observation group's adverse reaction rate is significantly lower than control
Group patient, wherein have between the incidence group of the adverse reactions such as perspiration, dry, nausea and vomiting, weight gain, blurred vision, headache
There is statistical difference, is shown in Table 16.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 17), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
The comparison of adverse reaction situation occurs during 16 two groups of patient's treatments of table
| Group | It perspires | Dry | Nausea and vomiting | Weight gain | Blurred vision | It is dizzy | Constipation/diarrhea | Headache |
| Observation group | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 1 |
| Control group | 5 | 10 | 12 | 5 | 6 | 5 | 6 | 6 |
| P | 0.197 | 0.010 | 0.002 | 0.421 | 0.031 | 0.197 | 0.108 | 0.108 |
Note: total number of cases are less than 40, using Fisher exact propability.
The type that 17. random forest of table analysis treatment group enteric bacteria content dramatically increases
8 medical stone of embodiment treats functional consitipation research
(1) prepared by preparation: medical stone being crushed, high pressure sterilization is spare.Auxiliary material is high-quality dry corn flour, medical stone Chinese medicine
Powder and corn flour mixed proportion are medical stone powder: corn flour: soya bean is 1:3:1 (mass ratio), and tablet, each tabletting weight is made
Amount is 0.5 gram, is made rear spare.
(2) functional consitipation subject selection: 70 patients are randomly divided into treatment group and control group.Treatment group 35, male 16
Example, female 19, the age 35~71 years old, average (44.4 ± 10.3) year.The course of disease 1~10 year, average (6.3 ± 4.6) year；Control group
35, male 17, female 18, the age 35~70 years old, average (43.9 ± 9.9) year；The course of disease 1~10 year, average (6.7 ± 5.8)
Year.Two groups of subject Genders, age, course of disease no difference of science of statistics.Selected case meets functional consitipation diagnostic criteria (sieve
Horse II standard).
(3) treatment method: treatment group takes orally 3 above-mentioned medical stone tablets daily, and 3 tablets once.Control group is using mutually year-on-year
The auxiliary material processing of example.Therapeutic effect evaluation and test is carried out after medication 1 month.
(4) it treatment effectiveness evaluation: is formulated referring to the adult constipation criterion of therapeutical effect in " disease of tcm Standardization of diagnosis and curative effect ".
(1) cure: defecation 1 time in 1 day, just matter is normal, and defecation is unobstructed, without recurrence in 1 month；(2) effective: defecation 1 time in 2 days, just
Matter tends to normally, and defecation is unobstructed, without recurrence in 1 month；(3) effectively: defecation 1 time in 3 days, just matter turns profit, and defecation owes smooth；(4)
Invalid: clinical symptoms are not improved.It is efficient with healing, the total calculating of effective case load.
(5) result: treated effect as the result is shown is shown in Table 18.According to statistical analysis, treatment group and the clinical of control group are treated
There were significant differences (P < 0.001) for effect.It has no adverse reaction.
(6) enteric microorganism changes: using high-flux sequence instrument sequencing analysis 16s rRNA, as the result is shown treatment group's enteron aisle
The diversity of microorganism dramatically increases (P ﹤ 0.01), and random forest (Random Forests) is analysis shows that (table 19), actinomyces
Door bacterial species and quantity dramatically increase (P ﹤ 0.01).
Curative effect compares (n, %) after 18 two groups of patients of table treat 1 month
| Group | N | It cures | It is effective | Effectively | In vain | Effective number of cases | It is efficient |
| Treatment group | 35 | 24 | 5 | 3 | 3 | 32 | 91.4% |
| Control group | 35 | 5 | 5 | 3 | 22 | 13 | 37.1% |
Note: through Chi-square Test: df=1, X2=22.462, P < 0.001.
The type that 19. random forest of table analysis treatment group enteric bacteria content dramatically increases
Above-described embodiment is only the preferred technical solution of the present invention, and is not construed as limitation of the invention, the present invention
Protection scope should with claim record technical solution, including claim record technical solution in technical characteristic etc.
It is protection scope with alternative, i.e., equivalent replacement within this range is improved, also within protection scope of the present invention.
Claims (10)
1. medical stone is in preparation prevention and/or treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance phase
Application in related disorders drug.
2. medical stone improves immunity of organisms, improves the diversity of enteric microorganism and promotes a variety of growth of probiotics in preparation
Application in drug.
3. application according to claim 1, which is characterized in that the anaphylactia includes allergic dermatitis, allergy
Property rhinitis, allergic asthma, anaphylactoid purpura, anaphylactic shock, irritable bowel disorder, allergic nephritis, anaphylaxis thyroiditis
And interstitial cystitis.
4. application according to claim 3, which is characterized in that the allergic dermatitis include drug rash, contact dermatitis,
Eczema, nettle rash, dermographism, food hypersenstivity and environmental factor cause allergy dermatitis；Irritable bowel disorder includes anaphylaxis knot
Enteritis, ulcerative colitis and Crohn disease.
5. application according to claim 1, which is characterized in that the mental disorder include depression, autism or
Senile dementia disease.
6. application according to claim 1, which is characterized in that the metabolism class disease include high blood pressure, diabetes or
Obesity.
7. application according to claim 1, which is characterized in that the endocrine disturbance related disease include whelk,
Female irregular menstruation disease, sleep disturbance are hard and dry and constipation.
8. application according to claim 1, which is characterized in that medical stone and pharmaceutically acceptable carrier are prepared into mouth
Formulation or external preparation.
9. application according to claim 2, which is characterized in that medical stone increases the type and quantity of actinomyces door bacterium.
10. application according to claim 2, which is characterized in that medical stone can reduce antibiotic for intestinal microecology
It influences, restores balance as early as possible after promoting the used antibiotic of intestinal microecology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811391195.1A CN109157540A (en) | 2018-11-21 | 2018-11-21 | Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811391195.1A CN109157540A (en) | 2018-11-21 | 2018-11-21 | Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109157540A true CN109157540A (en) | 2019-01-08 |
Family
ID=64875175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811391195.1A Pending CN109157540A (en) | 2018-11-21 | 2018-11-21 | Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109157540A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063966A (en) * | 2019-04-12 | 2019-07-30 | 东南大学 | Soil preparation and the preparation method and application thereof with prevention and treatment serum antibody exception related disease |
| CN111494313A (en) * | 2020-05-25 | 2020-08-07 | 李会芳 | Enema for treating sow constipation and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102982A (en) * | 1993-11-24 | 1995-05-31 | 董光辉 | China medicinal stone active oral solution and preparing method |
| CN1935157A (en) * | 2005-09-22 | 2007-03-28 | 黄景霖 | Medical stone emulsifiable paste for treating skin disease and its preparing method |
| CN201847298U (en) * | 2010-11-23 | 2011-06-01 | 赖新莲 | Healthy pillow |
| TW201132363A (en) * | 2010-03-24 | 2011-10-01 | New Century Creative System Service Co Ltd | Cosmetic compositions and its carrier |
| CN104435428A (en) * | 2014-11-29 | 2015-03-25 | 黄根强 | Traditional Chinese medicine composition for treating depression |
| CN204273975U (en) * | 2014-12-06 | 2015-04-22 | 周伟 | Multifunctional bio magnetic is rested the head on |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
| CN108686219A (en) * | 2018-05-30 | 2018-10-23 | 东南大学 | A kind of nutrition intestinal flora prevents and/or the minerals as traditional Chinese medicine and inorganic salts compound formulation for the treatment of anaphylactia |
-
2018
- 2018-11-21 CN CN201811391195.1A patent/CN109157540A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102982A (en) * | 1993-11-24 | 1995-05-31 | 董光辉 | China medicinal stone active oral solution and preparing method |
| CN1935157A (en) * | 2005-09-22 | 2007-03-28 | 黄景霖 | Medical stone emulsifiable paste for treating skin disease and its preparing method |
| TW201132363A (en) * | 2010-03-24 | 2011-10-01 | New Century Creative System Service Co Ltd | Cosmetic compositions and its carrier |
| CN201847298U (en) * | 2010-11-23 | 2011-06-01 | 赖新莲 | Healthy pillow |
| CN104435428A (en) * | 2014-11-29 | 2015-03-25 | 黄根强 | Traditional Chinese medicine composition for treating depression |
| CN204273975U (en) * | 2014-12-06 | 2015-04-22 | 周伟 | Multifunctional bio magnetic is rested the head on |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
| CN108686219A (en) * | 2018-05-30 | 2018-10-23 | 东南大学 | A kind of nutrition intestinal flora prevents and/or the minerals as traditional Chinese medicine and inorganic salts compound formulation for the treatment of anaphylactia |
Non-Patent Citations (3)
| Title |
|---|
| 王光宇等: "《320种中药及其微量元素》", 30 June 2018 * |
| 谢丽玲等: "果蝇头部烟碱乙酰胆碱受体的随龄变化及麦饭石的抗衰老作用", 《暨南大学学报》 * |
| 高颖: "《中医临床诊疗指南释义.脑病分册》", 30 September 2015, 中国中医药出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063966A (en) * | 2019-04-12 | 2019-07-30 | 东南大学 | Soil preparation and the preparation method and application thereof with prevention and treatment serum antibody exception related disease |
| CN111494313A (en) * | 2020-05-25 | 2020-08-07 | 李会芳 | Enema for treating sow constipation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109157541A (en) | Application of the kaolin in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| CN108888630A (en) | Application of the humus flava usta in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| Taibi et al. | A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia | |
| Udani et al. | Effects of kivia powder on Gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study | |
| CN1973889A (en) | Insomnia treating Chinese medicine | |
| Abbasi Fakhravari et al. | The effect of foot reflexology massage on the sleep quality of elderly women with restless leg syndrome | |
| CN109893544A (en) | For preventing and treating the soil preparation and the preparation method and application thereof of metabolism class disease | |
| CN112294924A (en) | Heart-nourishing and nerve-soothing pharmaceutical composition and preparation method and application thereof | |
| Dehghanmehr et al. | Effect of oral saffron capsules on sleep quality in patients with diabetes at Zabol-Iran | |
| CN109157540A (en) | Application of the medical stone in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| CN109288858A (en) | Application of the ginger chunk in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| CN109172602A (en) | Application of the montmorillonite in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| CN110101715A (en) | Soil preparation and the preparation method and application thereof with prevention and treatment neuroendocrine disorders related disease | |
| CN110354227A (en) | Application containing soil material in the drug or health care product of preparation prevention and/or treatment immune system disorder disease | |
| CN110354228A (en) | Application containing soil material in preparation prevention and/or treatment metabolism class disease medicament or health care product | |
| CN108635555A (en) | A kind of traditional Chinese medicine acupoint emplastrum and preparation method thereof for treating depressive disorder | |
| CN110384713A (en) | Application of the red halloysite in preparation prevention and treatment anaphylactia, mental disorder, metabolism class disease and endocrine disturbance disease medicament | |
| CN107625917A (en) | A kind of Charred Triplet tea bag for treating infantile indigestion with food retention and preparation method thereof | |
| CN110420220A (en) | Application containing soil material in preparation prevention and/or treatment endocrine disturbance disease medicament or health care product | |
| CN110464739A (en) | Application containing soil material in preparation prevention and/or treatment mental disorder drug or health care product | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| Nezakati et al. | The comparison of effect of abdominal massage and chewing sugar-free gum on the incidence and severity of constipation in male patients undergoing skeletal traction of lower limbs: A single-blind clinical trial | |
| CN1679692A (en) | Medicine for gonorrhea and its preparation | |
| Archer et al. | Milmed treatment alleviated or abolished allergy | |
| CN112654358A (en) | Lactobacillus combination for relieving irritable bowel syndrome and for relieving other gastrointestinal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190108 |
|
| RJ01 | Rejection of invention patent application after publication |